FGFR2 and cholangiocarcinoma: A phase II (NCT02265341) is registered to determine the efficacy of ponatinib, a type IIA multi-target tyrosine kinase inhibitor, in patients with advanced cholangiocarcinomas harboring FGFR2 fusions [57].